1. Home
  2. GERN vs OLPX Comparison

GERN vs OLPX Comparison

Compare GERN & OLPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • OLPX
  • Stock Information
  • Founded
  • GERN 1990
  • OLPX 2014
  • Country
  • GERN United States
  • OLPX United States
  • Employees
  • GERN N/A
  • OLPX N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • OLPX Package Goods/Cosmetics
  • Sector
  • GERN Health Care
  • OLPX Consumer Discretionary
  • Exchange
  • GERN Nasdaq
  • OLPX Nasdaq
  • Market Cap
  • GERN 823.0M
  • OLPX 947.3M
  • IPO Year
  • GERN 1996
  • OLPX 2021
  • Fundamental
  • Price
  • GERN $1.24
  • OLPX $1.12
  • Analyst Decision
  • GERN Buy
  • OLPX Buy
  • Analyst Count
  • GERN 7
  • OLPX 4
  • Target Price
  • GERN $3.17
  • OLPX $1.88
  • AVG Volume (30 Days)
  • GERN 7.6M
  • OLPX 847.3K
  • Earning Date
  • GERN 11-06-2025
  • OLPX 11-06-2025
  • Dividend Yield
  • GERN N/A
  • OLPX N/A
  • EPS Growth
  • GERN N/A
  • OLPX N/A
  • EPS
  • GERN N/A
  • OLPX N/A
  • Revenue
  • GERN $164,447,000.00
  • OLPX $423,083,000.00
  • Revenue This Year
  • GERN $172.62
  • OLPX $1.81
  • Revenue Next Year
  • GERN $56.87
  • OLPX $2.86
  • P/E Ratio
  • GERN N/A
  • OLPX N/A
  • Revenue Growth
  • GERN 11877.20
  • OLPX N/A
  • 52 Week Low
  • GERN $1.09
  • OLPX $1.01
  • 52 Week High
  • GERN $4.50
  • OLPX $2.28
  • Technical
  • Relative Strength Index (RSI)
  • GERN 43.70
  • OLPX 30.83
  • Support Level
  • GERN $1.19
  • OLPX $1.18
  • Resistance Level
  • GERN $1.31
  • OLPX $1.26
  • Average True Range (ATR)
  • GERN 0.07
  • OLPX 0.06
  • MACD
  • GERN -0.01
  • OLPX -0.01
  • Stochastic Oscillator
  • GERN 17.31
  • OLPX 5.56

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About OLPX Olaplex Holdings Inc.

Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.

Share on Social Networks: